Division of Gastroenterology, Department of Internal Medicine and Gastrointestinal Cancer Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Gastrointest Endosc. 2018 Mar;87(3):800-808. doi: 10.1016/j.gie.2017.09.023. Epub 2017 Oct 3.
The U.K. guidelines for risk stratification after colon polypectomy differ from the U.S. guidelines in 2 ways: the U.K. guidelines consider ≥5 adenomas as high risk and do not consider histology (villous or high-grade dysplasia) in the assessment. Thus, we aimed to investigate the risk of advanced colorectal neoplasm (CRN) by categorized risk groups, considering both ≥5 adenomas and histology.
A total of 2570 patients with ≥1 adenoma at index colonoscopy were included. The patients were divided into 6 groups: group 1, 1 to 2 non-advanced adenomas (non-AAs) ≥10 mm or high-grade dysplasia or villous adenoma; group 1A, 1 to 2 adenomas with ≥1 advanced adenoma (AA); group 2, 3 to 4 non-AAs; group 2A, 3 to 4 adenomas with ≥1 AA; group 3, ≥5 non-AAs; and group 3A, ≥5 adenomas with ≥1 AA. The risk of advanced CRN at 3 years was compared among the 6 groups.
Group 3A showed a higher risk of advanced CRN (9.6%) than group 3 (4.5%; P = .03) and group 1A (4.6%; P < .001). The risk of advanced CRN in group 3 (4.5%) showed no difference compared with group 1A (4.6%; P = .91) or group 2A (6.8%; P = .25). There was no difference between group 1 and group 2 in the risk of advanced CRN (1.7% vs 2.2%; P = .22). More than 1 AA at index colonoscopy was an independent risk factor for advanced CRN.
More-intensive surveillance than the 3-year interval for patients with ≥5 adenomas with ≥1 AA and less-intensive surveillance than the 3-year and 1-year intervals for those with 3 to 4 non-AAs and ≥5 non-AAs, respectively, might be suggested.
英国结肠息肉切除术后风险分层指南与美国指南在 2 个方面存在差异:英国指南认为≥5 个腺瘤为高危,且不考虑组织学(绒毛状或高级别异型增生)在评估中的作用。因此,我们旨在通过分类风险组,同时考虑≥5 个腺瘤和组织学,来研究进展期结直肠肿瘤(CRN)的风险。
共纳入 2570 例在首次结肠镜检查时发现≥1 个腺瘤的患者。患者被分为 6 组:第 1 组,1 至 2 个非高级别腺瘤(非 AA)≥10mm 或高级别异型增生或绒毛状腺瘤;第 1A 组,1 至 2 个腺瘤伴≥1 个高级别腺瘤(AA);第 2 组,3 至 4 个非 AA;第 2A 组,3 至 4 个腺瘤伴≥1 个 AA;第 3 组,≥5 个非 AA;第 3A 组,≥5 个腺瘤伴≥1 个 AA。比较 6 组患者在 3 年内发生进展期 CRN 的风险。
第 3A 组发生进展期 CRN 的风险(9.6%)高于第 3 组(4.5%;P=0.03)和第 1A 组(4.6%;P<0.001)。第 3 组(4.5%)发生进展期 CRN 的风险与第 1A 组(4.6%)或第 2A 组(6.8%)相比无差异(P=0.91)。第 1 组与第 2 组发生进展期 CRN 的风险(1.7%比 2.2%;P=0.22)无差异。首次结肠镜检查时发现多个 AA 是发生进展期 CRN 的独立危险因素。
对于≥5 个伴≥1 个 AA 的腺瘤患者,建议比 3 年间隔更密集的监测;对于 3 至 4 个非 AA 和≥5 个非 AA 的患者,建议比 3 年和 1 年间隔更不密集的监测。